Researchers Find Link Between Graft-Versus-Host Disease and Sexual Dysfunction

A common and serious condition affecting some patients following a stem cell transplant may also be leading to sexual dysfunction.

Researchers from the City of Hope Cancer Research Hospital in Duarte, Calif., where many stem cell transplants are done annually, are reporting in the journal Blood that graft-versus-host disease (GVHD) – the complication following a transplant in which the graft (stem cells) begin attacking the host – is a possible cause of sexual dysfunction and diminished sexual health in these patients.

The study

Investigators identified 277 adults (152 men and 125 women) who had a stem cell transplant between 2001 and 2005 at City of Hope and asked them to complete three questionnaires five separate times: 17 days before the SCT procedure, and six, 12, 24 and 36 months after the procedure.

Two of the questionnaires concerned sexual function, namely with questions about sexual cognition, sexual arousal, sexual behavior/experience, orgasm and sex drive/relationship, while the third concerned quality of life.

Decline in sexual satisfaction

In those patients who had chronic GVHD, there was a 21 percent decline in sexual cognition/fantasy in men and a 24 percent decline in the quality of orgasm. Women with chronic GVHD reported a 27 percent decline in sexual satisfaction and the same decline percentage in sexual arousal.

In sum, investigators determined that almost half of survivors in the study were sexually inactive within three years of the procedure.

"It is not often that the transplant team and patient will have a conversation about how this procedure could impact their sex life, even after recovery," said lead author Dr. Lennie Wong. "However, we hope these findings will help encourage patients and their doctors to openly discuss concerns related to sexual dysfunction and address them with specialists who can help."

Source: MNT

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap